Article information
Full text is only available in PDF
Bibliografía
[1.]
L.C. Tsui, M. Buchwald, D. Barker, J.C. Braman, R. Knowlton, J.W. Schumm, et al.
Cystic fibrosis locus defined by a genetically linked polymorphic DNA marker.
Science, 29 (1985), pp. 1054-1057
[2.]
F. Ratjen, G. Doring.
Cystic fibrosis.
Lancet, 22 (2003), pp. 681-689
[3.]
R.L. Gibson, J.L. Burns, B.W. Ramsey.
Pathophysiology and management of pulmonary infections in cystic fibrosis.
Am J Respir Crit Care Med, 15 (2003), pp. 918-951
[4.]
D.H. Andersen.
Cystic fibrosis of the pancreas and its relation to celiac disease. A clinical and pathological study.
Am J Dis Child, 56 (1938), pp. 344-399
[5.]
P.A. Lewis.
The epidemiology of cystic fibrosis.
Cystic fibrosis, pp. 1-13
[6.]
Cystic Fibrosis Foundation. Patient Registry 2001 Annual Data report. Bethesda: Cystic Fibrosis Foundation; 2002.
[7.]
M. Szaff, N. Hoiby, E.W. Flensborg.
Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection.
Acta Pediatr Scand, 72 (1983), pp. 651-657
[8.]
J.B. Lyczak, C.L. Cannon, G.B. Pier.
Lung infection associated with cystic fibrosis.
Clin Microbiol Rews, 15 (2002), pp. 194-222
[9.]
A. Oliver, R. Cantón, P. Campo, F. Baquero, J. Blázquez.
High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection.
Science, 288 (2000), pp. 1251-1254
[10.]
S. Rajan, L. Saiman.
Pulmonary infections in patients with cystic fibrosis.
Semin Respir Infect, 17 (2002), pp. 47-56
[11.]
M. Rosenfeld, B.W. Ramsey, R.L. Gibson.
Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management.
Curr Opin Pulm Med, 9 (2003), pp. 492-497
[12.]
J. Emerson, M. Rosenfeld, S. McNamara, B. Ramsey, R.L. Gibson.
Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.
Pediatr Pulmonol, 34 (2002), pp. 91-100
[13.]
J. De Gracia, A. Álvarez, F. Mata, L. Guarner, M. Vendrell, S. Gartner, et al.
Fibrosis quística del adulto: estudio de 111 pacientes.
Med Clin (Barc), 119 (2002), pp. 605-609
[14.]
S.H. Donaldson, R.C. Boucher.
Update on the pathogenesis of cystic fibrosis lung disease.
Curr Opin Pulm Med, 9 (2003), pp. 486-491
[15.]
J.J. Smith, S.M. Travis, E.P. Greenberg, M.J. Welsh.
Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid.
Cell, 86 (1996), pp. 1-20
[16.]
K.A. Brogden, M.R. Ackermann, P.B. McCray Jr, K.M. Huttner.
Differences in the concentrations of small, anionic, antimicrobial peptides in bronchoalveolar lavage fluid and in respiratory epithelia of patients with and without cystic fibrosis.
Infect Immun, 67 (1999), pp. 4256-4259
[17.]
W.B. Guggino.
Cystic fibrosis salt/fluid controversy: in the thick of it.
Nat Med, 7 (2001), pp. 888-889
[18.]
G.B. Pier, M. Grout, T.S. Zaidi, J.C. Olsen, L.G. Johnson, J.R. Yankaskas, et al.
Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections.
Science, 27 (1996), pp. 64-67
[19.]
J.F. Chmiel, M. Berger, M.W. Konstan.
The role of inflammation in the pathophysiology of CF lung disease.
Clin Rev Allergy Immunol, 23 (2002), pp. 5-27
[20.]
N.T. Petersen, N. Hoiby, C.H. Mordhorst, K. Lind, E.W. Flensborg, B. Bruun.
Respiratory infections in cystic fibrosis caused by virus, chlamydia and mycoplasma – Possible synergism with Pseudomonas aeruginosa.
Acta Paediatr Scand, 70 (1981), pp. 623-628
[21.]
D. Wat, I. Doull.
Respiratory virus infections in cystic fibrosis.
Paediatr Respir Rev, 4 (2003), pp. 172-177
[22.]
J.L. Burns, R.L. Gibson, S. McNamara, D. Yim, J. Emerson, M. Rosenfeld, et al.
Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis.
J Infect Dis, 183 (2001), pp. 444-452
[23.]
D.P. Speert, M.E. Campbell, D.A. Henry, R. Milner, F. Taha, A. Gravelle, et al.
Epidemiology of Pseudomonas aeruginosa in cystic fibrosis in British Columbia, Canada.
Am J Respir Crit Care Med, 166 (2002), pp. 988-993
[24.]
M. Griese, I. Muller, D. Reinhardt.
Eradication of initial Pseudomonas aeruginosa colonization in patients with cystic fibrosis.
Eur J Med Res, 7 (2002), pp. 79-80
[25.]
M. Rosenfeld, R.L. Gibson, S. McNamara, J. Emerson, J.L. Burns, R. Castile, et al.
Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis.
Pediatr Pulmonol, 32 (2001), pp. 356-366
[26.]
J.R. Govan, V. Deretic.
Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia.
Microbiol Rev, 60 (1996), pp. 539-574
[27.]
N. Renders, H. Verbrugh, A. Van Belkum.
Dynamics of bacterial colonisation in the respiratory tract of patients with cystic fibrosis.
Infect Genet Evol, 1 (2001), pp. 29-39
[28.]
A. Munck, S. Bonacorsi, P. Mariani-Kurkdjian, M. Lebourgeois, M. Gerardin, N. Brahimi, et al.
Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization.
Pediatr Pulmonol, 32 (2001), pp. 288-292
[29.]
J.H. Maselli, M.K. Sontag, J.M. Norris, T. MacKenzie, J.S. Wagener, F.J. Accurso.
Risk factors for initial acquisition of Pseudomonas aeruginosa in children with cystic fibrosis identified by newborn screening.
Pediatr Pulmonol, 35 (2003), pp. 257-262
[30.]
S.E. West, L. Zeng, B.L. Lee, M.R. Kosorok, A. Laxova, M.J. Rock, et al.
Respiratory infections with Pseudomonas aeruginosa in children with cystic fibrosis: early detection by serology and assessment of risk factors.
JAMA, 287 (2002), pp. 2958-2967
[31.]
H.R. Stutman, J.M. Lieberman, E. Nussbaum, M.I. Marks.
Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial.
J Pediatr, 140 (2002), pp. 299-305
[32.]
M.R. Kosorok, M. Jalaluddin, P.M. Farrell, G. Shen, C.E. Colby, A. Laxova, et al.
Comprehensive analysis of risk factors for acquisition of Pseudomonas aeruginosa in young children with cystic fibrosis.
Pediatr Pulmonol, 26 (1998), pp. 81-88
[33.]
S.H. Abman, J.W. Ogle, R.J. Harbeck, N. Butler-Simon, K.B. Hammond, F.J. Accurso.
Early bacteriologic, immunologic, and clinical courses of young infants with cystic fibrosis identified by neonatal screening.
J Pediatr, 119 (1991), pp. 211-217
[34.]
M.R. Kosorok, L. Zeng, S.E. West, M.J. Rock, M.L. Splaingard, A. Laxova, et al.
Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition.
Pediatr Pulmonol, 32 (2001), pp. 277-287
[35.]
Y. Aron, B.S. Polla, T. Bienvenu, J. Dall’ava, D. Dusser, D. Hubert.
HLA class II polymorphism in cystic fibrosis. A possible modifier of pulmonary phenotype.
Am J Respir Crit Care Med, 159 (1999), pp. 1464-1468
[36.]
G. Doring, H. Krogh-Johansen, S. Weidinger, N. Hoiby.
Allotypes of alpha 1-antitrypsin in patients with cystic fibrosis, homozygous and heterozygous for deltaF508.
Ped Pulmonol, 18 (1994), pp. 3-7
[37.]
Y. Loubieres, D. Grenet, B. Simon-Bouy, J. Medioni, P. Landais, C. Ferec, et al.
Association between genetically determined pancreatic status and lung disease in adult cystic fibrosis patients.
Chest, 121 (2002), pp. 73-80
[38.]
P.D. Arkwright, S. Laurie, M. Super, V. Pravica, M.J. Schwarz, A.K. Webb, et al.
TGF-beta(1) genotype and accelerated decline in lung function of patients with cystic fibrosis.
Thorax, 55 (2000), pp. 459-462
[39.]
J. Hull, A.H. Thomson.
Contribution of genetic factors other than CFTR to disease severity in cystic fibrosis.
Thorax, 53 (1998), pp. 1018-1021
[40.]
R.L. Henry, C.M. Mellis, L. Petrovic.
Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis.
Pediatr Pulmonol, 12 (1992), pp. 158-161
[41.]
R.B. Parad, C.J. Gerard, D. Zurakowski, D.P. Nichols, G.B. Pier.
Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype.
Infect Immun, 67 (1999), pp. 4744-4750
[42.]
C.A. Demko, P.J. Byard, P.B. Davis.
Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection.
J Clin Epidemiol, 48 (1995), pp. 1041-1049
[43.]
G.M. Nixon, D.S. Armstrong, R. Carzino, J.B. Carlin, A. Olinsky, C.F. Robertson, et al.
Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis.
J Pediatr, 138 (2001), pp. 699-704
[44.]
T. Pressler.
IgG subclasses and chronic bacterial infection. Subclass antibodies and the clinical course of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.
APMIS Suppl, 66 (1996), pp. 1-41
[45.]
H.R. Stutman, M.I. Marks.
Pulmonary infections in children with cystic fibrosis.
Semin Respir Infect, 2 (1987), pp. 166-176
[46.]
S. Ballestero, H. Escobar, R. Villaverde, P. Negredo, M. Elia, M. Ojeda- Vargas, et al.
Microbiological parameters and clinical evolution in cystic fibrosis.
Clinical ecology of cystic fibrosis, pp. 55-62
[47.]
A. Oliver, F. Baquero, J. Blázquez.
The mismatch repair system (mutS, mutL and uvrD genes) in Pseudomonas aeruginosa: molecular characterization of naturally occurring mutants.
Mol Microbiol, 43 (2002), pp. 1641-1650
[48.]
D.H. Spencer, A. Kas, E.E. Smith, C.K. Raymond, E.H. Sims, M. Hastings, et al.
Whole-genome sequence variation among multiple isolates of Pseudomonas aeruginosa.
J Bacterial, 185 (2003), pp. 1316-1325
[49.]
R.K. Ernst, E.C. Yi, L. Guo, K.B. Lim, J.L. Burns, M. Hackett, et al.
Specific lipopolysaccharide found in cystic fibrosis airway Pseudomonas aeruginosa.
Science, 286 (1999), pp. 1561-1565
[50.]
S.S. Yoon, R.F. Hennigan, G.M. Hilliard, U.A. Ochsner, K. Parvatiyar, M.C. Kamani, et al.
Pseudomonas aeruginosa anaerobic respiration in biofilms: relationships to cystic fibrosis pathogenesis.
Dev Cell, 3 (2002), pp. 593-603
[51.]
R. Cantón, A. Oliver, F. Baquero.
Microbiología de las vías respiratorias en la fibrosis quística.
Fibrosis quística, atención integral, manejo clínico y puesta al día, pp. 105-158
[52.]
C.J. Henwood, D.M. Livermore, D. James, M. Warner, and the Pseudomonas Study Group.
Antimicrobial susceptibility of Pseudomonas aeruginosa: results of a UK survey and evaluation of the British Society for Antimicrobial Chemotherapy disc susceptibility test.
J Antimicrob Chemother, 47 (2001), pp. 789-799
[53.]
M. Rosenfeld, J. Emerson, F. Accurso, D. Armstrong, R. Castile, K. Grimwood, et al.
Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis.
Pediatr Pulmonol, 28 (1999), pp. 321-328
[54.]
D.S. Armstrong, K. Grimwood, J.B. Carlin, R. Carzino, A. Olinsky, P.D. Phelan.
Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis.
Pediatr Pulmonol, 21 (1996), pp. 267-275
[55.]
R. Suri, L.J. Marshall, C. Wallis, C. Metcalfe, J.K. Shute, A. Bush.
Safety and use of sputum induction in children with cystic fibrosis.
Pediatr Pulmonol, 35 (2003), pp. 309-313
[56.]
B. Frederiksen, C. Koch, N. Hoiby.
Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995).
Pediatr Pulmonol, 8 (1999), pp. 59-66
[57.]
A.L. Smith, S.B. Fiel, N. Mayer-Hamblett, B. Ramsey, J.L. Burns.
Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis.
Chest, 123 (2003), pp. 1495-1502
[58.]
Cystic Fibrosis Foundation Consensus care conferences concepts in care: microbiology and infectious disease in cystic fibrosis, May 17-18, 1994. En: Cystic Fibrosis Foundation, editor. Clinical practice guidelines; 1997.
[59.]
M.B. Miller, P.H. Gilligan.
Laboratory aspects of management of chronic pulmonary infections in patients with cystic fibrosis.
J Clin Microbiol, 41 (2003), pp. 4009-4015
[60.]
T.W. Lee, K.G. Brownlee, M. Denton, J.M. Littlewood, S.P. Conway.
Reduction in prevalence of chronic Pseudomonas aeruginosa infection at a regional pediatric cystic fibrosis center.
Pediatr Pulmonol, 37 (2004), pp. 104-110
[61.]
B. Nair, J. Stapp, L. Stapp, L. Bugni, J. Van Dalfsen, J.L. Burns.
Utility of gram staining for evaluation of the quality of cystic fibrosis sputum samples.
J Clin Microbiol, 40 (2002), pp. 2791-2794
[62.]
P.H. Gilligan.
Microbiology of airway disease in patients with cystic fibrosis.
Clin Microbiol Rev, 4 (1991), pp. 35-51
[63.]
G.L. Morlin, D.L. Hedges, A.L. Smith, J.L. Burns.
Accuracy and cost of antibiotic susceptibility testing of mixed morphotypes of Pseudomonas aeruginosa.
J Clin Microbiol, 32 (1994), pp. 1027-1030
[64.]
J.L. Burns, L. Saiman, S. Whittier, D. Larone, J. Krzewinski, Z. Liu, et al.
Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients.
J Clin Microbiol, 38 (2000), pp. 1818-1822
[65.]
S. Haussler, S. Ziesing, G. Rademacher, L. Hoy, H. Weissbrodt.
Evaluation of the Merlin, Micronaut system for automated antimicrobial susceptibility testing of Pseudomonas aeruginosa and Burkholderia species isolated from cystic fibrosis patients.
Eur J Clin Microbiol Infect Dis, 22 (2003), pp. 496-500
[66.]
L. Saiman, J.L. Burns, S. Whittier, J. Krzewinski, S.A. Marshall, R.N. Jones.
Evaluation of reference dilution test methods for antimicrobial susceptibility testing of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis.
J Clin Microbiol, 37 (1999), pp. 2987-2991
[67.]
E.F. Marley, C. Mohla, J.M. Campos.
Evaluation of E-Test for determination of antimicrobial MICs for Pseudomonas aeruginosa isolates from cystic fibrosis patients.
J Clin Microbiol, 33 (1995), pp. 3191-3193
[68.]
A. Oliver, B.R. Levin, C. Juan, F. Baquero, J. Blázquez.
Hypermutation and the pre-existence of antibiotic resistance in Pseudomonas aeruginosa: implications for susceptibility testing and treatment of chronic infections.
Antimicrob Agents Chemother, 48 (2004), pp. 4226-4233
[69.]
M.D. Macia, N. Borrell, J.L. Pérez, A. Oliver.
Detection and susceptibility testing of hypermutable Pseudomonas aeruginosa strains with the E-test and disk diffusion.
Antimicrob Agents Chemother, 48 (2004), pp. 2665-2672
[70.]
R.N. Chernish, S.D. Aaron.
Approach to resistant gram-negative bacterial pulmonary infections in patients with cystic fibrosis.
Curr Opin Pulm Med, 9 (2003), pp. 509-515
[71.]
S.M. Moskowitz, J.M. Foster, J. Emerson, J.L. Burns.
Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.
J Clin Microbiol, 42 (2004), pp. 1915-1922
[72.]
S.D. Aaron, W. Ferris, K. Ramotar, K. Vandemheen, F. Chan, R. Saginur.
Single and combination antibiotic susceptibilities of planktonic, adherent, and biofilm-grown Pseudomonas aeruginosa isolates cultured from sputa of adults with cystic fibrosis.
J Clin Microbiol, 40 (2002), pp. 4172-4179
[73.]
D. Worlitzsch, R. Tarran, M. Ulrich, U. Schwab, A. Cekici, K.C. Meyer, et al.
Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients.
J Clin Invest, 109 (2002), pp. 317-325
[74.]
M.T. Osterholm, C.W. Hedberg, K.A. Moore.
Epidemiologic principles.
5th ed., pp. 156-167
[75.]
V. Deretic, M.J. Schurr, H. Yu.
Pseudomonas aeruginosa, mucoid and the chronic infection phenotype in cystic fibrosis.
Trends Microbiol, 3 (1995), pp. 351-356
[76.]
S.S. Pedersen.
Lung infection with alginate-producing mucoid Pseudomonas aeruginosa in cystic fibrosis.
APMIS Suppl, 28 (1992), pp. 1-79
[77.]
M.L. Hutchison, J.R. Govan.
Pathogenecity of microbes associated with cystic fibrosis.
Microbes Infect, 1 (1999), pp. 1005-1014
[78.]
J.L. Burns, L. Saiman, S. Whittier, J. Krzewinski, Z. Liu, D. Larone, et al.
Comparison of two commercial systems (Vitek and MicroScan- WalkAway) for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Diagn Microbiol Infect Dis, 39 (2001), pp. 257-260
[79.]
S.D. Aaron, K. Ramotar, W. Ferris, K. Vandemheen, R. Saginur, E. Tullis, et al.
Adult cystic fibrosis exacerbations and new strains of Pseudomonas aeruginosa.
Am J Respir Crit Care Med, 69 (2004), pp. 811-815
[80.]
M. Denton, M.H. Wilcox.
Antimicrobial treatment of pulmonary colonization and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
J Antimicrob Chemother, 40 (1997), pp. 468-474
[81.]
B.W. Ramsey.
Management of pulmonary disease in patients with cystic fibrosis.
N Engl J Med, 335 (1996), pp. 179-188
[82.]
N. Cobos, S. Gartner, S. Liñán.
Fibrosis quística.
Manual de neumología y cirugía torácica, pp. 1217-1236
[83.]
G. Doring, S.P. Conway, H.G. Heijerman, M.E. Hodson, N. Hoiby, A. Smyth, et al.
Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus.
Eur Respir J, 16 (2000), pp. 749-767
[84.]
M.C. Walters, F. Roe, A. Bugnicourt, M.J. Franklin, P.S. Stewart.
Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin.
Antimicrob Agents Chemother, 47 (2003), pp. 317-323
[85.]
M.E. Hodson, C.G. Gallagher, J.R. Govan.
A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis.
Eur Respir J, 20 (2002), pp. 658-664
[86.]
S. Mukhopadhyay, M. Singh, J.I. Cater, S. Ogston, M. Franklin, R.E. Olver.
Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks.
Thorax, 51 (1996), pp. 364-368
[87.]
J.G. Den Hollander, A.M. Horrevorts, M.L. Van Goor, H.A. Verbrugh, J.W. Mouton.
Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model.
Antimicrob Agents Chemother, 41 (1997), pp. 95-100
[88.]
M. Mueller, A. De la Pena, H. Derendorf.
Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC.
Antimicrob Agents Chemother, 48 (2004), pp. 369-377
[89.]
J.T. Smith.
The mode of action of 4-quinolones and possible mechanisms of resistance.
J Antimicrob Chemother, 18 (1986), pp. 21-29
[90.]
I. Phillips Phillips, E. Culebras, F. Moreno, F. Baquero.
Induction of the SOS response by new 4-quinolones.
J Antimicrob Chemother, 20 (1987), pp. 631-638
[91.]
B.W. Gunderson, K.H. Ibrahim, L.B. Hovde, T.L. Fromm, M.D. Reed, J.C. Rotschafer.
Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model.
Antimicrob Agents Chemother, 47 (2003), pp. 905-909
[92.]
N.E. Moller, N. Hoiby.
Antibiotic treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis patients.
Scand J Infect Dis Suppl, 29 (1981), pp. 87-91
[93.]
M. Szaff, N. Hoiby.
Antibiotic treatment of Staphylococcus aureus infection in cystic fibrosis.
Acta Paediatr Scand, 71 (1982), pp. 21-26
[94.]
N. Parekh, P. Subbarao, N. Sweezey, A. Matlow, M. Corey.
Association between prophylactic antibiotic usage and and early onset of Pseudomonas aeruginosa.
Pediatr Pulmonol, 17 (1998), pp. 426A
[95.]
F. Ratjen, G. Doring, W.H. Nikolaizik.
Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis.
Lancet, 358 (2001), pp. 983-984
[96.]
B. Frederiksen, A. Hansen, C. Koch, N. Hoiby.
Delay of recurrence of Pseudomonas aeruginosa in patients with cystic fibrosis with inhaled colistin and oral ciproxin: a comparison between 3 weeks and 3 months of treatment.
Pediatr Pulmonol, (1997), pp. 298 A
[97.]
M.E. Hodson, C.M. Roberts, R.J. Butland, M.J. Smith, J.C. Batten.
Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis.
Lancet, 1 (1987), pp. 235-237
[98.]
I. Shalit, H.R. Stutman, M.I. Marks, S.A. Chartrand, B.C. Hilman.
Randomized study of two dosage regimens of ciprofloxacin for treating chronic bronchopulmonary infection in patients with cystic fibrosis.
Am J Med, 82 (1987), pp. 189-195
[99.]
D.A. Church, J.F. Kanga, R.J. Kuhn, T.T. Rubio, W.A. Spohn, J.C. Stevens, et al.
Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. Ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group.
Pediatr Infect Dis J, 16 (1997), pp. 97-105
[100.]
J.M. Littlewood, M.G. Miller, A.T. Ghoneim, C.H. Ramsden.
Nebulised colomycin for early Pseudomonas colonisation in cystic fibrosis.
Lancet, 1 (1985), pp. 865
[101.]
H.G. Wiesemann, G. Steinkamp, F. Ratjen, B. Przyklenk, G. Döring, H. Von der Hardt.
Placebo-controlled, double-blind, randomized study for early treatment of Pseudomonas aeruginosa colonization in patients with cystic fibrosis.
Pediatr Pulmonol, 25 (1998), pp. 88-92
[102.]
N. Valerius, C. Koch, N. Hoiby.
Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment.
Lancet, 338 (1991), pp. 725-726
[103.]
B.W. Ramsey, M.S. Pepe, J.M. Quan, K.L. Otto, A.B. Montgomery, J. Williams-Warren, et al.
Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
N Engl J Med, 340 (1999), pp. 23-30
[104.]
N. Hoiby.
Prospects for the prevention and control of pseudomonal infection in children with cystic fibrosis.
Paediatr Drugs, 2 (2000), pp. 451-463
[105.]
M. Nir, S. Lanng, H.K. Johansen, C. Koch.
Long-term survival and nutritional data in patients with cystic fibrosis treated in a Danish centre.
Thorax, 51 (1996), pp. 1023-1027
[106.]
G. Steinkamp, B. Tummler, M. Gappa, A. Albus, J. Potel, G. Doring, et al.
Long-term tobramycin aerosol therapy in cystic fibrosis.
Pediatr Pulmonol, 6 (1989), pp. 91-98
[107.]
T. Jensen, S.S. Pedersen, S. Garne, C. Heilmann, N. Hoiby, C. Koch.
Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection.
J Antimicrob Chemother, 19 (1987), pp. 831-838
[108.]
B.W. Ramsey, J. Burns, A.L. Smith.
Safety and efficacy of tobramycin solution for inhalation in patients with cystic fibrosis. The results of 2 phases placebo controlled trials.
Pediatr Pulmonol, 14 (1997), pp. 137-138
[109.]
D. Banerjee, D. Stableforth.
The treatment of respiratory Pseudomonas infection in cystic fibrosis: what drug and which way?.
Drugs, 60 (2000), pp. 1053-1064
[110.]
A.L. Smith, C. Doershuk, D. Goldmann, E. Gore, B. Hilman, M. Marks, et al.
Comparison of a β-lactam alone versus β-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibtrosis.
J Pediatr, 134 (1999), pp. 413-421
[111.]
J. De Gracia, L. Máiz, C. Prados, M. Vendrell, F. Baranda, A. Escribano, et al.
Conferencia de Consenso: Antibióticos nebulizados en pacientes con fibrosis quística.
Med Clin (Barc), 117 (2001), pp. 233-237
[112.]
F. Dapena, M. Ramos, I. Gómez.
Actualización terapéutica en fibrosis quística.
Inf Ter Sist Nac Salud, 27 (2003), pp. 129-144
[113.]
D.J. Touw.
Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis.
Pharm World Sci, 20 (1998), pp. 149-160
[114.]
E. Rey, J.M. Treluyer, G. Pons.
Drug disposition in cystic fibrosis.
Clin Pharmacokinet, 35 (1998), pp. 313-329
[115.]
D.J. Touw, A.A. Vinks, J.W. Mouton, A.M. Horrevorts.
Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Current practice and suggestions for future directions.
Clin Pharmacokinet, 35 (1998), pp. 437-459
[116.]
J.P. Wang, J.D. Unadkat, S.M. Al-Habet, T.A. O'Sullivan, J. Williams- Warren, A.L. Smith, et al.
Disposition of drugs in cystic fibrosis. IV. Mechanisms for enhanced renal clearance of ticarcillin.
Clin Pharmacol Ther, 54 (1993), pp. 293-302
[117.]
M.D. Reed, S.C. Aronoff, R.C. Stern, T.S. Yamashita, C.M. Myers, L.T. Friedhoff, et al.
Single-dose pharmacokinetics of aztreonam in children with cystic fibrosis.
Pediatr Pulmonol, 2 (1986), pp. 282-286
[118.]
A. Hedman, G. Alvan, B. Strandvik, A. Arvidsson.
Increased renal clearance of cefsulodin due to higher glomerular filtration rate in cystic fibrosis.
Clin Pharmacokinet, 18 (1990), pp. 168-175
[119.]
J.W. Bins, H. Mattie.
The tubular excretion of benzylpenicillin in patients with cystic fibrosis.
Br J Clin Pharmacol, 27 (1989), pp. 2 91-294
[120.]
K. Vance-Bryan, D.R.P. Guay, J.C. Rotschafer.
Clinical pharmacokinetics of ciprofloxacin.
Clin Pharmacokinet, 19 (1990), pp. 434-461
[121.]
P.A. Todd, P. Benfield.
Amoxicillin/clavulanic acid. An update of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Drugs, 39 (1990), pp. 264-307
[122.]
C.M. Perry, R.N. Brogden.
Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.
Drugs, 52 (1996), pp. 125-158
[123.]
D.H. Peters, H.A. Friedel, D. McTavish.
Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.
Drugs, 44 (1992), pp. 750-799
[124.]
C.P. Rains, H.M. Bryson, D.H. Peters.
Ceftazidime. An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.
Drugs, 49 (1995), pp. 577-617
[125.]
L.B. Barradell, H.M. Bryson.
Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Drugs, 47 (1994), pp. 471-505
[126.]
C.M. Perry, A. Markham.
Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections.
Drugs, 57 (1999), pp. 805-843
[127.]
M.M. Buckley, R.N. Brogden, L.B. Barradell, K.L. Goa.
Imipenem/cilastatin. A reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.
Drugs, 44 (1992), pp. 408-444
[128.]
L.R. Wiseman, A.J. Wagstaff, R.N. Brogden, H.M. Bryson.
Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.
Drugs, 50 (1995), pp. 73-101
[129.]
P.F. Smith, C.H. Ballow, B.M. Booker, A. Forrest, J.J. Schentag.
Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients.
Clin Ther, 23 (2001), pp. 1231-1244
[130.]
A. Aminimanizani, P.M. Beringer, J. Kang, L. Tsang, R.W. Jelliffe, B.J. Shapiro.
Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis.
J Antimicrob Chemother, 50 (2002), pp. 553-559
[131.]
F. Canis, M.O. Husson, D. Turck, P. Vic, V. Launay, S. Ategbo, et al.
Pharmacokinetics and bronchial diffusion of single daily dose amikacin in cystic fibrosis patients.
J Antimicrob Chemother, 39 (1997), pp. 431-433
[132.]
M. Boeckh, H. Lode, K. Borner, G. Höffken, J. Wagner, P. Koeppe.
Pharmacokinetics and serum bactericidal activity of vancomycin alone and in combination with ceftazidime in healthy volunteers.
Antimicrob Agents Chemother, 32 (1988), pp. 92-95
[133.]
L. Verbist, B. Tjandramaga, B. Hendrickx, A.N. Van Hecken, P. Van Melle, R. Verbesselt, et al.
In vitro activity and human pharmacokinetics of teicoplanin.
Antimicrob Agents Chemother, 26 (1984), pp. 881-886
[134.]
D.E. Geller, W.H. Pitlick, P.A. Nardella, W.G. Tracewell, B.W. Ramsey.
Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis.
Chest, 122 (2002), pp. 219-226
[135.]
J. Klastersky, D. Daneu, G. Swings, D. Weerts.
Antibacterial activity in serum and urine as a therapeutic guide in bacterial infections.
J Infect Dis, 129 (1974), pp. 187-193
[136.]
E.T. Anderson, L.S. Young, W.L. Hewitt.
Simultaneous antibiotic levels in “breakthrough” gram-negative rod bacteremia.
Am J Med, 61 (1976), pp. 493-497
[137.]
G.L. Drusano, P.A. Ryan, H.C. Standiford, M.R. Moody, S.C. Schimpff.
Integration of selected pharmacologic and microbiologic properties of three new β-lactam antibiotics: a hypothesis for rational comparison.
Rev Infect Dis, 6 (1984), pp. 357-363
[138.]
M.P. Weinstein, C.W. Stratton, H.B. Hawley, A. Ackley, H.B. Hawley, P.A. Robinson, et al.
Multicenter collaborative evaluation of a standarized serum bactericidal test as a prognostic indicator in infective endocarditis.
Am J Med, 78 (1985), pp. 262-269
[139.]
I. Mahmood, J.D. Bailan.
The pharmacokinetic principles behind scaling from preclinical results to phase I protocols.
Clin Pharmacokinet, 36 (1999), pp. 1-11
[140.]
R.C. Li, M. Zhu, J.J. Schentag.
Achieving an optimal outcome in the treatment of infections. The role of clinical pharmacokinetics and pharmacodynamics of antimicrobials.
Clin Pharmacokinet, 37 (1999), pp. 1-16
[141.]
W.A. Craig.
Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.
Clin Infect Dis, 26 (1998), pp. 1-12
[142.]
C.R. Marchbanks, J.R. McKiel, D.H. Gilbert, N.J. Robillard, B. Painter, S.H. Zinner, et al.
Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in a in vitro model of infection.
Antimicrob Agents Chemother, 37 (1993), pp. 1756-1763
[143.]
K.J. Madaras-Kelly, B.E. Ostergaard, L.B. Hovde, J.C. Rotschafer.
Twentyfour-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model.
Antimicrob Agents Chemother, 40 (1996), pp. 627-632
[144.]
R.C. Li, Z.Y. Zhu, S.W. Lee, K. Raymond, J.M. Ling, A.F.B. Cheng.
Antibiotic exposure and its relationship to postantibiotic effect and bactericidal activity: constant versus exponentially decreasing tobramycin concentrations against Pseudomonas aeruginosa.
Antimicrob Agents Chemother, 41 (1997), pp. 1808-1811
[145.]
M.J. Bouvier d’Yvoire, P.H. Maire.
Dosage regimens of antibacterials: implications of a pharmacokinetic/pharmacodynamic model.
Clin Drug Invest, 11 (1996), pp. 229-239
[146.]
J. Lipman, C.D. Gomersall, T. Gin, G.M. Joynt, R.J. Young.
Continuous infusion ceftazidime in intensive care: a randomized controlled trial.
J Antimicrob Chemother, 43 (1999), pp. 309-311
[147.]
M. Manduru, L.B. Mihm, R.L. White, L.V. Friedrich, P.A. Flume, J.A. Bosso.
In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Antimicrob Agents Chemother, 41 (1997), pp. 2053-2056
[148.]
J.Q. Tran, C.H. Ballow, A. Forrest, J.M. Hyatt, M.F. Sands, C.A. Peloquin, et al.
Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variables.
J Antimicrob Chemother, 45 (2000), pp. 9-17
[149.]
H. Permin, C. Koch, N. Hoiby, H.O. Christensen, A.F. Moller, S. Moller.
Ceftazidime treatment of chronic Pseudomonas aeruginosa respiratory tract infection in cystic fibrosis.
J Antimicrob Chemother, 12 (1983), pp. 313-323
[150.]
R. Gold, A. Overmeyer, B. Knie, P.C. Fleming, H. Levison.
Controlled trial of ceftazidime vs. ticarcillin and tobramycin in the treatment of acute respiratory exacerbations in patients with cystic fibrosis.
Pediatr Infect Dis, 4 (1985), pp. 172-177
[151.]
S. Stenvang Pedersen, T. Pressler, M. Pedersen, N. Hoiby, A. Friis- Moller, C. Koch.
Immediate and prolonged clinical efficacy of ceftazidime versus ceftazidime plus tobramycin in chronic Pseudomonas aeruginosa infection in cystic fibrosis.
Scand J Infect Dis, 18 (1986), pp. 133-137
[152.]
R. Padoan, W. Cambisano, D. Costantini, R.M. Crossignani, M.L. Danza, G. Trezzi, et al.
Ceftazidime monotherapy vs. combined therapy in Pseudomonas pulmonary infections in cystic fibrosis.
Pediatr Infect Dis J, 6 (1987), pp. 648-653
[153.]
W.A. Craig, S.C. Ebert.
Continuous infusion of beta-lactam antibiotics.
Antimicrob Agents Chemother, 36 (1992), pp. 2577-2583
[154.]
J.W. Mouton, A.A. Vinks.
Is continuous infusion of beta-lactam antibiotics worthwhile? Efficacy and pharmacokinetic considerations.
J Antimicrob Chemother, 38 (1996), pp. 5-15
[155.]
B. Byl, D. Baran, F. Jacobs, A. Herschuelz, J.P. Thys.
Serum pharmacokinetics and sputum penetration of amikacin 30 mg/kg once daily and of ceftazidime 200 mg/kg/day as a continuous infusion in cystic fibrosis patients.
J Antimicrob Chemother, 48 (2001), pp. 325-327
[156.]
F. Rougier, M. Ducher, M. Maurin, S. Corvaisier, D. Claude, R. Jelliffe, et al.
Aminoglycoside dosages and nephrotoxicity: quantitative relationships.
Clin Pharmacokinet, 42 (2003), pp. 493-500
[157.]
M. Rosenfeld, M. Cohen, B. Ramsey.
Aerosolized antibiotics for bacterial lower airway infections: principles, efficacy, and pitfalls.
Infect Dis Clin Pract, 7 (1998), pp. 66-79
[158.]
R. Beasley, D. Fishwick, J.F. Miles, L. Hendeles.
Preservatives in nebulizer solutions: risks without benefit.
Pharmacotherapy, 18 (1998), pp. 130-139
[159.]
M.E. Klepser.
Role of nebulized antibiotics for the treatment of respiratory infections.
Curr Opin Infect Dis, 17 (2004), pp. 109-112
[160.]
C.R. Catchpole, J.M. Andrews, N. Brenwald, R. Wise.
A reassessment of the in-vitro activity of colistin sulphomethate sodium.
J Antimicrob Chemother, 39 (1997), pp. 255-260
[161.]
G.S. Bauldoff, D.R. Nunley, J.D. Manzetti, J.H. Dauber, R.J. Keenan.
Use of aerosolized colistin sodium in cystic fibrosis patients awaiting lung transplantation.
Transplantation, 64 (1997), pp. 748-752
[162.]
B. Frederiksen, C. Koch, N. Hoiby.
Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis.
Pediatr Pulmonol, 23 (1997), pp. 330-335
[163.]
X. Zhao, K. Drlica.
Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window.
J Infect Dis, 185 (2002), pp. 561-565
[164.]
G. Kahlmeter.
Gentamicin and tobramycin. Clinical pharmacokinetics and nephrotoxicity. Aspects on assay techniques.
Scand J Infect Dis Suppl, 18 (1979), pp. 1-40
[165.]
Cantón R, García-Castillo MC, Morosini MI, Baquero MR, Oliver A, Baquero F. Mutant prevention concentrations (MPCs) in mutator and non-mutator Pseudomonas aeruginosa populations from cystic fibrosis patients. 43th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago 2003. Libro de resúmenes, resumen A-1320.
[166.]
J.J. LiPuma.
Microbiological and immunologic considerations with aerosolized drug delivery.
Chest, 120 (2001), pp. S118-S123
[167.]
T. Schulin.
In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southern Germany.
J Antimicrob Chemother, 49 (2002), pp. 403-406
[168.]
R. Cantón.
Interpretación del antibiograma en la elección del antibiótico y vía de administración.
Rev Clin Esp, 203 (2003), pp. 608-611
[169.]
J.L. Burns, J.M. Van Dalfsen, R.M. Shawar, K.L. Otto, R.L. Garber, J.M. Quan, et al.
Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis.
J Infect Dis, 179 (1999), pp. 1190-1196
[170.]
P.W. Campbell 3rd, L. Saiman.
Use of aerosolized antibiotics in patients with cystic fibrosis.
Chest, 116 (1999), pp. 775-788
[171.]
S.S. Pedersen, T. Jensen, N. Hoiby, C. Koch, E.W. Flensborg.
Management of Pseudomonas aeruginosa lung infection in Danish cystic fibrosis patients.
Acta Paediatr Scand, 76 (1987), pp. 955-961
[172.]
Cystic Fibrosis Trust Report of the UK Cystic Fibrosis Trust's Antibiotic Group: Antibiotic Treatment for Cystic Fibrosis. Cystic Fibrosis Trust; 2000.
[173.]
T. Jensen, S.S. Pedersen, C.H. Nielsen, N. Hoiby, C. Koch.
The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis.
J Antimicrob Chemother, 20 (1987), pp. 585-594
[174.]
T. Jensen, S.S. Pedersen, N. Hoiby, C. Koch, E.W. Flensborg.
Use of antibiotics in cystic fibrosis: the Danish approach.
Antibiotic Chemother, 42 (1989), pp. 237-246
[175.]
R.B. Moss.
Administration of aerosolized antibiotics in cystic fibrosis patients.
Chest, 120 (2001), pp. S107-S113
[176.]
P. Ball.
Emergent resistance to ciprofloxacin among Pseudomonas aeruginosa and Staphylococcus aureus: clinical significance and therapeutic approaches.
J Antimicrob Chemother, 26 (1990), pp. 165-179
[177.]
R. Cantón, R. Girón, L. Martínez-Martínez, A. Oliver, A. Solé, S. Valdezate, et al.
Patógenos multirresistentes en fibrosis quística.
Arch Bronconeumol, 38 (2002), pp. 376-385
[178.]
A. Escribano.
Diagnóstico y tratamiento de la exacerbación infecciosa en la fibrosis quística.
Arch Bronconeumol, 36 (2000), pp. 525-532
[179.]
S. Gartner, A. Moreno, N. Cobos.
Tratamiento de la enfermedad respiratoria en la fibrosis quística.
Tratado de neumología pediátrica, pp. 717-730
[180.]
Grupo de Trabajo de la SEPAR. Normativa sobre diagnóstico y tratamiento de la afección respiratoria en la fibrosis quística. En: SEPAR, editor. Recomendaciones SEPAR, 2001. N.° 29. Barcelona: Ediciones Doyma; 2001.
[181.]
Grupo de trabajo Fibrosis Quística.
Sociedad Española de Neumología Pediátrica. Protocolo de diagnóstico y seguimiento de los enfermos con fibrosis quística, 50 (1999), pp. 625-634
[182.]
L. Máiz, F. Baranda, R. Coll, C. Prados, M. Vendrell, A. Escribano, et al.
Normativas SEPAR. Normativa del diagnóstico y el tratamiento de la afección respiratoria en la Fibrosis Quística.
Arch Bronconeumol, 37 (2001), pp. 316-324
[183.]
M. Vendrell, J. De Gracia.
Antibioterapia inhalada.
Arch Bronconeumol, 33 (1997), pp. 41-48
[184.]
Conference de Consensus.
Prise en charge du patients attaint de mucoviscidose. Texte des recommandations (version courte) du thème 1 “pneumologie et infectologie”.
Rev Mal Respir, 20 (2003), pp. 149-157
[185.]
C. Koch, N. Hoiby.
Diagnosis and treatment of cystic fibrosis.
Respiration, 67 (2000), pp. 239-247
[186.]
J.R. Yankaskas, B.C. Marshall, B. Sufian, R.H. Simon, D. Rodman.
Cystic fibrosis adult care: consensus conference report.
Chest, 125 (2004), pp. S1-S39
[187.]
L. Saiman, J. Siegel.
Cystic Fibrosis Foundation Consensus Conference on Infection Control Participants. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission.
Am J Infect Control, 31 (2003), pp. S1-S62
[188.]
C. Vázquez, M. Municio, M. Corera, L. Gaztelurrutia, A. Sojo, J.C. Vitoria.
Early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis.
Acta Paediatr, 82 (1993), pp. 308-309
[189.]
F. Ratjen, G. Comes, K. Paul, H.G. Posselt, T.O. Wagner, K. Harms, and the German Board of the European Registry for Cystic Fibrosis (ERCF).
Effect of continuous antistaphylococcal therapy on the rate of P. aeruginosa acquisition in patients with cystic fibrosis.
Pediatr Pulmonol, 31 (2001), pp. 13-16
[190.]
G.M. Nixon, D.S. Armstrong, R. Carzino, J.B. Carlin, A. Olinsky, C.F. Robertson, et al.
Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis.
J Pediatr, 138 (2001), pp. 699-704
[191.]
C. Wainwright.
Early infection with Pseudomonas aeruginosa can be cleared in young children with cystic fibrosis.
North American Cystic Fibrosis Conference, (2002),
[192.]
K.H. Tan, M. Mulheran, A.J. Knox, A.R. Smyth.
Aminoglycoside prescribing and surveillance in cystic fibrosis.
Am J Respir Crit Care Med, 167 (2003), pp. 819-823
[193.]
G. Ryan, S. Mukhopadhyay, M. Singh.
Nebulised anti-pseudomonal antibiotics for cystic fibrosis.
Cochrane Database Syst Rev, (2003), pp. CD001021
[194.]
M.E. Hodson.
Treatment of cystic fibrosis in the adult.
Respiration, 67 (2000), pp. 595-607
[195.]
M.J. Ledson, M.J. Gallagher, C. Cowperthwaite, R.P. Convery, M.J. Walshaw.
Four years’ experience of intravenous colomycin in an adult cystic fibrosis unit.
Eur Respir J, 12 (1998), pp. 592-594
[196.]
B. Frederiksen, S. Lanng, C. Koch, N. Hoiby.
Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment.
Pediatric Pulmunol, 21 (1996), pp. 153-158
[197.]
A.L. Smith, G. Redding, C. Doershuk, D. Golman, E. Gore, B. Hilman, et al.
Sputum changes associated with therapy for endobronchial exacerbations in cystic fibrosis.
J Pediatr, 112 (1988), pp. 547-554
[198.]
W.E. Regelman, G.R. Elliot, W.J. Warwick, C.C. Clawson.
Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone.
Am Rev Respir Dis, 141 (1990), pp. 914-921
[199.]
B.C. Marshal, W.M. Samuelson.
Basic therapies in cystic fibrosis: does standard therapy work?.
Clin Chest Med, 19 (1989), pp. 487-504
[200.]
J.M. Wolter, S.D. Bowler, P.J. Nolan, J.G. McCormack.
Home intravenous therapy in cystic fibrosis: a prospective randomized trial examining clinical, quality of life and cost aspects.
Eur Respir J, 10 (1997), pp. 896-900
[201.]
T. Marco, O. Asensio, M. Bosque, J. De Gracia, C. Serra.
Home intravenous antibiotics for cystic fibrosis.
Cochrane Database Syst Rev, (2000),
[202.]
R.M. Girón, A. Martínez, L. Máiz, A. Salcedo, B. Beltrán, M.T. Martínez, et al.
Tratamiento antibiótico intravenoso domiciliario en las unidades de fibrosis quística de la Comunidad de Madrid.
Med Clin (Barc), 122 (2004), pp. 648-652
[203.]
S. Kudoh, T. Uetake, K. Hagiwara, M. Hirayama, L.H. Hus, H. Kimura, et al.
Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis.
Nihon Kyobu Shikkan Gakkai Zasshi, 25 (1987), pp. 632-642
[204.]
H. Homma, A. Yamanaka, S. Tanimoto, M. Tamura, Y. Chijimatsu, S. Kira, et al.
Diffuse panbronchiolitis. A disease of the transitional zone of the lung.
Chest, 83 (1983), pp. 63-69
[205.]
D. Lawrence.
Clues to mechanism of Pseudomonas resistance in cystic fibrosis.
Lancet, 359 (2002), pp. 1410
[206.]
A.S. Gaylor, J.C. Reilly.
Therapy with macrolides in patients with cystic fibrosis.
Pharmacotherapy, 22 (2002), pp. 227-239
[207.]
L. Máiz, R. Cantón.
Tratamiento con azitromicina en la fibrosis quística.
Med Clin (Barc), 122 (2004), pp. 311-316
[208.]
J. Wolter, S. Seeney, S. Bell, S. Bowler, P. Masel, J. McCormack.
Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial.
Thorax, 57 (2002), pp. 212-216
[209.]
A. Equi, I.M. Balfour-Lynn, A. Bush, M. Rosenthal.
Long term azithromycin in children with cystic fibrosis: a randomised, placebo- controlled crossover trial.
Lancet, 360 (2002), pp. 978-984
[210.]
L. Saiman, B.C. Marshall, N. Mayer-Hamblett, J.L. Burns, A.L. Quittner, D.A. Cibene, Macrolide Study Group, et al.
Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.
JAMA, 290 (2003), pp. 1749-1756
[211.]
L. Saiman, Y. Chen, P.S. Gabriel, C. Knirsch.
Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis.
Antimicrob Agents Chemother, 46 (2002), pp. 1105-1107
[213.]
D. Wales, M. Woodhead.
Anti-inflammatory effects of macrolides.
Thorax, 54 (1999), pp. S58-S62
[214.]
K. Tateda, R. Comte, J.C. Pechere, T. Kohler, K. Yamaguchi, C. Van Delden.
Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa.
Antimicrob Agents Chemother, 45 (2001), pp. 1930-1933
[215.]
P.M. Beringer, M.D. Appleman.
Unusual respiratory bacterial flora in cystic fibrosis: microbiologic and clinical features.
Curr Op Pulm Med, 6 (2000), pp. 545-550
[216.]
M. Ballmann, P. Rabsch, H. Von der Hardt.
Long term follow up changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonization in patients with cystic fibrosis.
Thorax, 53 (1998), pp. 732-737
[217.]
S.S. Wang, S.C. FitzSimmons, L.A. O’Leary, M.J. Rock, M.L. Gwinn, M.J. Khoury.
Early diagnosis of cystic fibrosis in the newborn period and risk of Pseudomonas aeruginosa acquisition in the first 10 years of life: a registry-based longitudinal study.
Pediatrics, 107 (2001), pp. 274-279
[218.]
L. Saiman.
Microbiology of early CF lung disease.
Paediatr Respir Rev, 5 (2004), pp. S367-S369
[219.]
F.F. Long, R.G. Castile, A.S. Brody, M.J. Hogan, R.L. Flucke, D.A. Filbrun, et al.
Lungs in infants and young children: improved thin section CT with noninvasive controlled-ventilation techniqueinitial experience.
Radiology, 212 (1999), pp. 588-593
[220.]
R.G. Castile, D. Filbrun, R. Flucke, W. Frankline, K. McCoy.
Adult type pulmonary function tests in infants without respiratory diseases.
Pediatr Pulmonol, 30 (2000), pp. 215-227
[221.]
D.J. Turner, C.J. Lanteri, P.N. LeSouef, P.D. Sly.
Improved detection of abnormal respiratory function using forced expiration from raised lung volume in infants with cystic fibrosis.
Eur Respir J, 7 (1994), pp. 1995-1999
[222.]
J.D. Antuni, S.A. Kharitonov, D. Hughes, M.E. Hodson, P.J. Barnes.
Increase in exhaled carbon monoxide during exacerbations of cystic fibrosis.
Thorax, 55 (2000), pp. 138-142
[223.]
E. Kerem, J. Reisman, M. Corey, G.J. Canny, H. Levison.
Prediction of mortality in patients with cystic fibrosis.
N Engl J Med, 326 (1992), pp. 1187-1191
[224.]
A. Pamukcu, A. Bush, R. Buchdahl.
Effects of Pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis.
Pediatr Pulmonol, 19 (1995), pp. 10-15
[225.]
G. Steinkamp, G.B. Tümmler, R. Malottke, U. Von der Hardt.
Treatment of Pseudomonas colonisation in cystic fibrosis.
Arch Dis Chile, 64 (1988), pp. 1022-1028
[226.]
C.E. Milla, W.J. Warwick.
Risk of death in cystic fibrosis patients with severely compromised lung function.
Chest, 113 (1998), pp. 1230-1234
[227.]
M. Gappa, S.C. Ranganathan, J. Stocks.
Lung function testing in infants with cystic fibrosis: lessons from the past and future directions.
Pediatr Pulmonol, 32 (2001), pp. 228-245
[228.]
American Thoracic Society/European Respiratory Society.
Respiratory mechanics in infants: physiologic evaluation in health and disease.
Am Rev Resp Dis, 147 (1993), pp. 474-496
[229.]
D.M. Orenstein.
Exercise testing in cystic fibrosis.
Pediatr Pulmonol, 25 (1998), pp. 223-225
[230.]
M.A. Jorquera, A. Salcedo, J.R. Villa, R.M. Girón, M.A. Neira, A. Sequeiros.
Reproductibilidad del test de la marcha (walking test) en pacientes afectos de fibrosis quística.
An Esp Ped, 51 (1999), pp. 475-478
[231.]
L.V. Da Silva Filho, J.E. Levi, C.N. Bento, J.C. Rodrigues, S.R. Da Silvo Ramos.
Molecular epidemiology of Pseudomonas aeruginosa infections in a cystic fibrosis outpatient clinic.
J Med Microbiol, 50 (2001), pp. 261-267
[232.]
F.B. Spencker, S. Haupt, M.C. Claros, S. Walter, T. Lietz, R. Schille, et al.
Epidemiologic characterization of Pseudomonas aeruginosa in patients with cystic fibrosis.
Clin Microbiol Infect, 6 (2000), pp. 600-607
[233.]
F.J. McLaughlin, W.J. Matthews Jr, D.J. Strieder, B. Sullivan, A. Taneja, P. Murphy, et al.
Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillinplacebo.
J Infect Dis, 147 (1983), pp. 559-567
[234.]
H.K. Johansen, N. Hoiby.
Seasonal onset of initial colonization and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis.
Thorax, 47 (1992), pp. 109-111
[235.]
F. Santamaria, G. Grillo, G. Guidi, A. Rotondo, V. Raia, G. De Ritis, et al.
Cystic fibrosis: when should high-resolution computed tomography of the chest be obtained?.
Pediatrics, 101 (1998), pp. 908-913
[236.]
A.S. Brody.
Cystic fibrosis: when should high-resolution computed tomography of the chest should be obtained?.
Pediatrics, 101 (1998), pp. 1071
[237.]
A. Jaffe, R. Hamutcu, R.T. Dhawan, B. Adler, M. Rosenthal, A. Bush.
Routine ventilation scans in children with cystic fibrosis: diagnostic usefulness and prognostic value.
Eur J Nucl Med, 28 (2001), pp. 1313-1318
[238.]
W.A. Rutala, D.J. Weber.
Disinfection and sterilization in health care facilities: what clinicians need to know.
Clin Infect Dis, 39 (2004), pp. 702-709
Grupo Español de Consenso del Tratamiento Antimicrobiano del Paciente con Fibrosis Quística, con participación de la Sociedad Española de Fibrosis Quística (SEFQ): J. Dapena, L. Máiz y C. Vázquez; Sociedad Española de Neumología Pediátrica (SENP): C. Antelo, N. Cobos, S. Gartner y A. Salcedo; Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC): R. Cantón, L. Martínez-Martínez y A. Oliver; Sociedad Española de Quimioterapia (SEQ): F. Baquero, E. García-Quetglas y J. Honorato; Sociedad Española de Neumología y Cirugía Torácica (SEPAR): A. Álvarez, L. Borderías, J. de Gracia y M. Vendrell.
Copyright © 2005. Sociedad Española de Neumología y Cirugía Torácica
